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ABSTRACT 
Introduction  
To determine the spectrum of aetiological agents in adult Community Acquired 
Pneumonia (CAP) admitted to an academic hospital in Johannesburg using a novel 
transport medium (PrimeStore™ MTM), in addition to traditional specimen 
processing.  PrimeStore™ MTM preserves released nucleic acids, including labile 
RNA.   
 
 Materials and Methods 
Forty-eight adult patients with radiologically confirmed CAP were prospectively 
studied over three months.  Microbiological investigation included culture from blood 
and sputum, with pulmonary tuberculosis being excluded by sputum microscopy and 
culture.  Nasopharyngeal swabs (PrimeStore™ MTM) were analysed using two 
commercial multiplex PCR assays for the detection of 6 major bacteria and 12 major 
respiratory viruses.  The BinaxNOW Legionella urinary antigen test was also used.  
 
Results  
A probable microbial aetiology of CAP was established for 62.5% (30 of the 48 
patients) when the PCR platform was added to the conventional methods with the 
use of the PrimeStore™ MTM swabs.  In contrast, the definite bacterial aetiology 
was 16.7% (8 of 48 patients) when conventional culture methods were used; none 
had more than one bacterial species identified.  Five patients had no aetiological 
pathogens determined.  The urine Legionella pneumophila antigen was negative in 
all patients.  Of the eight patients (16.7%) with a definite bacterial aetiology; 
Streptococcus pneumoniae was isolated from blood cultures of all eight patients. 
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Blood and sputum cultures were negative in 5 patients, but the clinical and 
radiological reporting was indicative of Pneumocystis jiroveci pneumonia with a 
positive BDG>500.  For this group of patients the term possible aetiology was 
introduced. 
 
Conclusion 
The five most prevalent pathogens identified were Streptococcus pneumoniae, 
Haemophilus influenzae, human rhinovirus, coronaviruses and metapneumovirus. 
The use of PrimeStore™ MTM significantly enhanced the diagnostic yield in 
determining the microbial aetiology of CAP in adult patients. 
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CHAPTER 1: INTRODUCTION 
 
1.1 Background 
Community-acquired pneumonia (CAP) is a common, potentially life-threatening 
infectious disease.  Pneumonia affects about 12 individuals per 1000 annually in the 
United States (Guthrie, 2001), resulting in approximately 1 million patient 
hospitalisations annually (Arnold et al., 2003), with a mortality of 13.6% (Dean et al., 
2001), and a cost of 10 billion US dollars annually (Gross et al., 2003).  
 
CAP is a common infection in all age groups and is the most important lower 
respiratory tract infection.  The demographics of the general patient population have 
changed over recent years.  This includes an increase in the number of individuals 
over the age of 65 years, and the number of immune-compromised patients, 
especially in association with human immunodeficiency virus (HIV) infection (Luna et 
al., 2000).  These factors have significantly increased the number of individuals at 
risk of pneumonia, the number of infections that occur, and the variety of pathogens 
found in association with the infection.  
 
1.2 Epidemiology of CAP in South Africa 
Despite the accessibility to effective vaccines and potent antimicrobials, in a 2008 
Statistics South Africa report on mortality and causes of death, second to 
tuberculosis as the leading cause of death in the South Africa (12.6% of natural 
causes of death), the other most common causes of natural death were influenza 
and pneumonia (7.7%) (Statistics South Africa,  2008). 
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Despite the use of many microbiological techniques, in nearly 50% of cases of CAP 
the aetiology is unknown (Steinhoff et al., 1996).  A study was undertaken to 
determine the aetiology of CAP in South Africa in 1987 where a cohort of 178 ICU 
admissions with severe CAP was reviewed.  In that study, the incidence of Gram-
negative bacteria causing infections was 15% (predominantly Klebsiella 
pneumoniae), the incidence of Staphylococcus aureus was 8% and Legionella 
pneumophila was 5% (Potgieter and Hammond, 1992).  
 
A retrospective analysis of data of all patients admitted to the then Hillbrow Hospital 
ICU in Johannesburg, between 1982 and December 1992 was analysed to assess 
the aetiology of severe CAP (Feldman et al., 1995).  The most common organism 
shown by Feldman et al. (1995) was Streptococcus pneumoniae (51.3%) and the 
second commonest organism was Klebsiella pneumoniae (31.9%). 
 
A prospective study carried out on adult patients in Cape Town at Groot Schuur 
Hospital with pneumonia from July 1987 to July 1988 found 35.9% of patients to be 
infected with atypical bacteria namely;  Chlamydophila pneumoniae (20,7%) and 
Legionella pneumophila (8,7%) (Maartens et al., 1994).  
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1.3 Aetiology of CAP  
1.3.1 Bacterial aetiology 
Numerous pathogens are listed as aetiological agents of CAP.  In a review of 26 
clinical trials in a cohort of adult patients who were hospitalised with CAP, it was 
found that a responsible organism was identified in only 3349 (33.7%) of 9933 
patients (Echols et al., 2008).  Among the patients for whom an aetiological 
pathogen was identified, in the atypical pathogen group there were 601 patients 
(17.9%) and in the bacterial pathogen group there were 2748 patients (82%).  The 
bacterial pathogens were Streptococcus pneumoniae, Haemophilus influenzae, and 
Staphylococcus aureus, and the atypical pathogens were Mycoplasma pneumoniae, 
Chlamydophila pneumoniae, and Legionella pneumophila. 
 
Most studies identify Streptococcus pneumoniae as the most common aetiological 
organism in CAP (Jokinen et al., 2001).  Other bacterial agents including 
Haemophilus influenzae and atypical pathogens (Mycoplasma pneumoniae, 
Chlamydophila pneumoniae, Coxiella burnetii and Legionella pneumophila) are 
described in up to 35% of CAP episodes (Jokinen et al., 2001). 
 
The Neufield Quellung typing method has been the “gold standard” for 
Streptococcus pneumoniae (Lalitha et al., 1996).  The traditional method of 
serotyping Streptococcus pneumoniae uses pneumococcal typing anti-sera obtained 
from Statens Seruminstitut, Copenhagen, Denmark.   
 
Pneumococcal conjugate vaccine (PCV) usage has reduced the burden of invasive 
disease due to vaccine types (i.e., serotypes 4, 6B, 9V, 14, 18C, 19F, 23F).  Vaccine 
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efficacy has led to significant decreases in morbidity and mortality due to 
Streptococcus pneumoniae in the young with vaccine-serotype invasive 
pneumococcal disease being 83% in HIV-uninfected children compared to 65% in 
HIV-infected children (Madhi et al., 2012).  Disease management has been 
complicated by the unexpected increase in resistant serotypes, such as 19A.  
 
Serotype 1 is among the most prevalent invasive serotypes across the world (Garcia 
et al., 2006).  Among vaccine serotypes, serotype 4 was significantly associated with 
invasive disease.  Serotypes 1, 2, 7, 9, 14, and 16 were noted among the most 
invasive serotypes, and serotypes 3, 6, 15, 19, and 23 were among the least 
invasive serotypes (Smith et al., 1993).  
 
1.3.2 Viral aetiology 
The outbreaks of severe acute respiratory syndrome (SARS) and human cases of 
H5N1 influenza infection have shifted attention towards viral pneumonias.  The 
identification of human metapneumovirus has led to numerous studies seeking to 
clarify the role of this virus in human respiratory tract infections (Crowe, 2004).  
Human bocavirus (Arnold et al., 2003) and human coronavirus NL6311 have been 
associated with CAP in children and adults (Van Der Hoek et al., 2006).  As optimal 
replication of rhinovirus is restricted at higher core body temperature it was initially 
thought that its replication was prevented in the lower respiratory tract.  However 
increasing evidence indicates that rhinovirus, may be associated with CAP in 
children and adults (Hayden, 2004) though its role in pneumonia still remains 
controversial.  
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Respiratory viruses are recognised as aetiological agents of CAP, with influenza 
virus being one of the leading viral pathogens (Ruiz et al., 1999).  Current studies 
based on molecular diagnostics indicate that viruses acknowledged as the causative 
agent of CAP may have been underestimated because of a previous limited range of 
diagnostic options and methods (Murdoch, 2004).  
 
It is unclear whether a virus on its own causes pneumonia or whether the virus acts 
in conjunction with other respiratory pathogens.  Some studies have proven that 
some respiratory viral pathogens are capable of invading and multiplying in the lower 
respiratory tract mucosa (Papadopoulos et al., 2000).  In addition, a few cases 
indicate that the incidence of mixed infections may be quite significant among 
patients admitted to hospital with CAP (Madhi et al., 2006).   
 
The major causes of viral CAP in adults reported in literature are influenza A/B, 
parainfluenza virus (PIV) type 1(PIV1), PIV2, PIV3, respiratory syncytial virus (RSV), 
adenovirus, and rhinovirus (Domachowske and Rosenberg, 1999).  Other viruses 
such as coronavirus (CoV), bocavirus, enterovirus, PIV4, the newly discovered 
parvovirus types 4 and 5, and mimivirus (Dare et al., 2008) have also been proven to 
infect the respiratory tract, but at a much lower frequency.  The clinical significance 
of bocavirus, parvovirus types 4 and 5, and mimivirus is not known. 
 
Rhinoviruses and CoVs were identified as human pathogens in the 1960s, but they 
have been largely ignored by the medical community because their clinical impact 
was uncertain (Tyrrell and Bynoe, 1965).  It is now clear that rhinoviruses and CoVs 
may cause fatal CAP.  All of the viruses mentioned above have similar clinical 
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presentations of CAP and attending clinicians cannot distinguish the aetiological 
agent without a proven laboratory diagnosis (Chiu et al., 2005). 
 
Traditionally, rhinoviruses have been undiagnosed for several reasons.  First, 
rhinovirus infections were not considered to be aetiological agents of CAP by 
clinicians.  Second, the traditional culture of this virus is rather complex and tedious 
(Landry, 2007).  Thirdly, rhinoviruses were neglected by clinicians, and no diagnosis 
by monoclonal antibodies has been developed.  Lastly, rhinovirus serotypes make 
the possibility of broadly reacting antibodies unlikely since they lack a common group 
antigen (Arruda et al., 1996). 
 
Since 2000, avian influenza viruses (H5N1, H7N7, and H7N3), human 
metapneumovirus (hMPV), severe acute respiratory syndrome (SARS) CoV, and 
human CoVs (HCoV) NL63 and HKU1 have emerged (Cheng et al., 2007). 
 
Human MPV causes CAP and the signs and symptoms are very similar to those 
caused by RSV (Van den Hoogen et al., 2003).  Human MPV outbreaks occur 
predominantly in the winter in temperate climates, often following the winter RSV 
outbreak (Kaida et al., 2006).  Human MPV infections can be diagnosed by using 
serology, virus isolation, and antigen or nucleic acid detection.  The major 
disadvantage of cell culture is the length of time required to identify a virus and its 
poor sensitivity (Boivin et al., 2002). 
 
The human coronaviruses are the largest of all RNA viruses.  There are five HCoVs, 
which include 229E, OC43, SARS-CoV, NL63, and HKU1 (Vallet et al., 2004).  
20 
 
 
 
HKU1 was discovered in January 2004 in a 71-year-old man returning to Hong Kong 
from Shenzhen, presenting with fever and a productive purulent cough with a chest 
radiograph showing patchy infiltrates (Woo et al., 2005).  All attempts to grow a virus 
failed, however CoV RNA was detected by RT-PCR. 
 
There have been numerous studies from over 12 countries reporting bocavirus 
prevalence ranging from 2 to 11% in respiratory tract specimens, indicating that the 
virus has a worldwide distribution (Kesebir et al., 2006).  
 
Despite multiple studies identifying influenza virus as an identifiable aetiological 
pathogen of adult hospitalised patients with CAP, especially during a known 
influenza season, anti-influenza antiviral agents are uncommonly used empirically for 
CAP.  Often clinicians wait for viral confirmation of influenza infection before 
prescribing antiviral treatment.  However, in a routine clinical setting, diagnostic 
testing for influenza is rare, the more common rapid diagnostic methods have low 
sensitivity, and the more sensitive diagnostic methods such as RT-PCR are neither 
readily available nor affordable (Murdoch, 2004). 
  
A primary viral pneumonia with a subsequent bacterial infection is also a recognised 
entity.  In a cohort of patients admitted with (outside of influenza season) CAP, 
influenza was frequently found as a co-pathogen alongside other respiratory 
pathogens such as Streptococcus pneumoniae (Markos et al., 2006).  Recently, 
radiological evidence of pneumonia was observed in 18-66% of patients hospitalised 
with confirmed H1N1 influenza (Mu et al., 2010). 
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The management of CAP in adults has traditionally focused little on potential viral 
causes.  This situation is largely due to the lack of specific antiviral agents and the 
impression that viral pathogens play a relatively minor role in adult pneumonia 
(Hayden, 2006).  Increasing awareness that adult CAP is commonly associated with 
viral infections, the potential impact of viral vaccines and the increasing availability of 
antiviral chemotherapeutic agents should direct researchers and clinicians to focus 
more on the role of respiratory viruses in adult CAP.  
 
Furthermore, mixed infections involving bacterial and other viral pathogens are 
common and mixed rhinovirus/pneumococcal infection appears to be associated with 
severe pneumonia (Hayden, 2006).  It is likely that the prevalence of both viral and 
mixed bacterial-viral infection is even higher than currently estimated.  Further 
research should focus on the better characterisation of the viral burden in adult CAP 
and the interaction between bacterial and viral pathogens (Pevear et al., 2005).  The 
use of empiric antiviral therapy, in addition to empiric antibiotic therapy should be 
considered in our current CAP guidelines. 
 
1.3.3 Atypical aetiology 
The atypical pneumonias could be classified as those that are of zoonotic origin 
which includes psittacosis, Q fever, and tularaemia, and the non-zoonotic agents 
which include Chlamydophila pneumoniae, Mycoplasma pneumonia and Legionella 
pneumophila.  Both the zoonotic and non-zoonotic atypical pneumonias differ mainly 
from bacterial CAP with regards to the presence or absence of extra-pulmonary 
features.  
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“Atypical” pathogens are an important cause of CAP in a very specific subset of the 
population (elderly adults, tobacco smokers, immune-compromised and those with 
chronic illnesses such as chronic obstructive pulmonary disease) should be 
considered in aetiologic studies to capture epidemiological changes.  An example is 
the prevalence of Chlamydophila pneumoniae in a study that showed cyclic variation 
(van der Eerden et al., 2005).  
 
The clinical importance of the atypical pneumonias is not only closely linked to their 
clinical incidence, but rather on other clinical and public health aspects (Murray and 
Tuazon, 1980).  The atypical pneumonias require antibiotics that inhibit or eradicate 
microorganisms (Sopena et al., 1998) such as macrolides and doxycyline.  Studies 
confirm that atypical bacterial pathogens frequently co-infect patients with CAP, 
possibly in as much as one-third of cases of pneumococcal pneumonia (Ortqvist et 
al., 1990).  Atypical pathogens are often under recognised unless specifically tested 
for by serology or molecular detection (Houck et al., 2001).  
 
Mycoplasma pneumoniae is difficult to culture, and routine diagnosis is dependent 
on serology.  Multiple primers for PCR-based detection of Mycoplasma pneumoniae 
have been developed for respiratory specimens but there may be a poor correlation 
between antibody response and PCR because the pathogen could be detected in 
patients without respiratory disease or remain undetected in patients with respiratory 
manifestations (Daxboeck et al., 2003). 
 
 Legionellosis clinically presents as two distinct entities:  (i) Legionnaires’ disease, a 
severe disease presenting as pneumonia and (ii) Pontiac fever, an influenza-like 
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illness (Fields et al., 2002).  Legionnaires’ disease manifests as a more acute and 
severe clinical picture than either chlamydial or mycoplasmal CAP.  This is probably 
due to its ability to multiply intracellularly as well as its ability to avoid lysosomal 
destruction (Swanson and Hammer, 2000).  A diagnostic tool is the urinary antigen 
test (Plouffe et al., 1995).  The test is both highly sensitive and specific for Legionella 
pneumophila serogroup 1.  A positive urinary antigen test on the day of admission 
indicates Legionnaires' disease.  However, a negative test does not exclude the 
possibility of infection since this assay is limited to those who are infected with 
Legionella pneumophila serogroup 1.  Those with mild disease due to other 
Legionella serogroups may also have a negative urinary antigen test. 
 
During the period 11 November 1985 - 21 February 1986, 12 cases of Legionnaires' 
disease were identified at a Johannesburg teaching hospital.  Only 2 patients were 
proven to have acquired the disease in hospital.  An epidemiological investigation 
was undertaken which proved that the aetiological agent might have been acquired 
from a wide variety of water sources.  Legionella pneumophila was cultured from the 
hospital hot-water system.  Cases were clustered in the medical and surgical 
intensive care units.  This was the first investigation of an outbreak of Legionnaires' 
disease in South Africa (Strebel et al., 1988). 
 
1.3.4 Fungal aetiology 
Even though CAP caused by fungi is not a common aetiology in the general 
population, pathology in a rapidly expanding immune-compromised population is 
encountered increasingly (Miyashita et al., 2001).  Other directed epidemiological 
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studies have described the growing incidence of fungal pneumonia in high-risk 
groups such as those with AIDS (Bochud et al., 2001). 
 
The diagnosis of Pneumocystis jiroveci pneumonia (PJP) has always been a 
challenge given the difficulty in culturing the responsible pathogen.  Detection of 
Pneumocystis jirovecii (formerly known as Pneumocystis carinii f. sp. hominis) often 
relies on immune-fluorescent microscopy, and sensitivity is affected by sampling 
variability and experience of the technician.  The results depend on the quality of the 
sample thus supporting the recommendation for routine induced sputum in these 
cases (Pitchenik et al., 1986).   Molecular based diagnostics could improve PCP 
diagnosis by detection of DNA (Arcenas et al., 2006).   
 
The Fungitell assay (Associates of Cape Cod, Inc.) intended for diagnosis of invasive 
fungal infections is a commercial test that detects (1→3)-β-D-glucan.  (1→3)-β-D-
glucan (BDG) is a component of the cell wall of fungi.  Its presence in the 
bloodstream correlates with a possible aetiology of PJP (or other invasive fungal 
infections).  Studies suggest that the Fungitel assay may be useful in the 
presumptive diagnosis of invasive fungal infections (Pickering et al., 2005).  Staining 
with monoclonal antibodies for Pneumocystis jirovecii  has gradually been replaced 
by BDG serum levels as a diagnostic assay with high negative predictive value and 
sensitivity and specificity above 80% for the diagnosis of PJP (Acosta et al., 2011).  
 
1.4 Risk factors   
Risk factors have been defined for a number of pathogens, including both typical 
bacteria and atypical organisms.  A recent review of the aetiology of CAP listed 
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some of these factors (Apisarnthanarak and Mundy, 2005).  Recognized risk factors 
for Streptococcus pneumoniae, the most common of the aetiological agents of CAP, 
include dementia associated with old age, seizure disorders, cardiac pathology, 
cerebrovascular disease, chronic obstructive pulmonary disease, HIV infection, 
African race, overcrowded living conditions, and smoking.  Risk factors for 
Staphylococcus aureus include advanced age, chronic lung pathology, and previous 
antibiotic use, whereas the risk factors for Haemophilus influenzae are chronic 
obstructive pulmonary disease treated with repeated cycles of antibiotics or oral 
steroids. 
 
1.5 Empiric treatment  
Since an aetiological diagnosis of CAP is usually unknown, the initial empirical 
treatment is often guided by microbial patterns described with regards to the risk 
categories.  The increased mortality in patients with severe CAP who do not receive 
empiric antibiotics that cover the infecting pathogens has been well studied (Leroy et 
al., 1995).  Although conventional tests such as sputum and blood cultures have 
limited value in some cases of CAP (Waterer and Wunderink, 2001), an aetiological 
identification is relatively likely and aetiological-directed therapy is associated with a 
better outcome in patients with severe CAP (Van der Eerden et al., 2005). 
 
Recommended antibiotic therapy differs between the various guidelines and is most 
likely due to differences of infections caused by CAP organisms, in antibiotic 
resistance, and in the interpretation of the clinical relevance as well as antibiotic 
licensing.  
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 The challenge at the time that the clinician is providing treatment to a hospitalised 
patient with CAP is that he or she neither knows what the aetiological pathogen is 
nor knows its susceptibility patterns.  Since the aetiological agent of CAP is often 
outdated and not determined locally, the initial empirical treatment is guided by 
microbial pathogens described for specific risk categories (Lim et al., 2003).  For 
example, the currently available guidelines for CAP management advocate empirical 
antibiotic treatment based on the age of the patient, present co-morbidities and initial 
assessment of the severity of the illness (Lim et al., 2009).   
 
Recommendations of empiric antimicrobial treatment according to the severity 
assessment are routinely based on the concept that the risk of adverse outcomes in 
patients receiving inadequate initial antimicrobial treatment increases with 
pneumonia severity (Roson et al., 2001).  This includes excess mortality.  
 
Guidelines for the treatment and prevention of CAP were first proposed by a 
European Respiratory Society (ERS) task force in collaboration with the European 
Society for Clinical Microbiology and Infectious Diseases (ESCMID) (Woodhead et 
al., 2005).  Consensus guidelines from American Thoracic Society, Infectious 
Diseases Society of America, and Canadian Guidelines for the initial management of 
CAP advocate empiric therapy with macrolides, fluoroquinolones, or doxycycline 
(Mandell et al., 2001).  The Therapeutic Working Group of the CDC discourages the 
use of fluoroquinolones due to potential resistance concerns. 
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Adherence to CAP guidelines also allows the screening of patients into those that 
need admission and those who don’t and can be managed as outpatients (Marrie et 
al., 2000). 
 
The main disagreement against a pathogen directed approach is the lack of 
sensitivity and specificity of the routine diagnostic methods currently employed 
(Niederman et al., 2001).  For this reason, sputum examination by gram stain and 
culture were not recommended by the American Thoracic Society guidelines.  
Another argument against a pathogen directed approach is that atypical bacterial 
pathogens such as Mycoplasma pneumoniae, Chlamydophila pneumoniae and 
Legionella pneumophila, for which the prevalence ranges from 8% to 63%, cannot 
be identified by conventional microbiological methods during the first days of 
treatment (Fang et al., 1990). 
 
The South African Guidelines for Community acquired pneumonia in adults was last 
updated by a working group of the South African Thoracic Society, which included 
members of the Critical Care Society of Southern Africa, and the Federation of 
Infectious Diseases Societies of Southern Africa in 2007.   Serological testing for 
‘atypical pathogens’, additional tests for microbial antigens or antibodies and 
polymerase chain reaction techniques are not recommended. 
 
According to the Working Group of the South African Thoracic Society the treatment 
of choice for CAP in severely ill adults “is a combination of parenteral amoxycillin-
clavulanate or a second or third generation cephalosporin or ertapenem in specific 
circumstances, together with an aminoglycoside (gentamicin or amikacin or 
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tobramycin) and a macrolide (erythromycin, clarithromycin or azithromycin)” 
(Feldman et al., 2007).  The aminoglycoside is added initially because of the 
relatively high prevalence of CAP associated with aerobic Gram-negative bacilli 
documented previously in various intensive care unit studies in South Africa.  Single 
daily dosing is recommended for the aminoglycosides, together with routine 
monitoring of trough serum drug levels.  Aminoglycosides may be discontinued if 
organisms other than Gram-negative bacteria are isolated.  Aminoglycosides are 
best avoided, or used with extreme caution, in the elderly and in patients with renal 
impairment (Feldman et al., 2007). 
 
Empiric ertapenem should only be used in patients who have failed standard first-line 
antibiotic therapy for CAP, particularly as part of directed antibiotic therapy based on 
the results of microbiological testing (Feldman et al., 2007). 
 
Considering the limitations of current diagnostic tests for viral confirmation, empiric 
therapy for viral causes CAP is an option as testing is more expensive (Mc Greer et 
al., 2007). 
 
Seasonal and year-to-year variations in multiple studies indicate that, during 
numerous influenza seasons, an estimated 10%–15% of adult patients with 
pneumonia and/or symptomatic pulmonary pathology are likely to be caused by 
influenza virus (Jennings et al., 2008).  
 
As the rates of viral and atypical pathogens are very similar in CAP, adequate 
treatment should be of consideration (Arnold et al., 2007). 
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1.6 Risk assessments 
Clinicians estimate the severity of pneumonia and fail to recognise those at higher 
risk; therefore all guidelines recommend that clinical findings should be 
supplemented by objective severity scoring.  Two main scoring systems are 
commonly in use: the pneumonia severity index (PSI) and CURB-65. PSI (Appendix 
4) classifies patients in terms of their expected mortality based on the presence of co 
morbidity, vital signs and laboratory abnormalities.  The CURB-65 (Appendix 3) 
score provides a guide to identify more severely ill patients on the basis of only five 
variables (Ewig et al., 2006).   
 
The decision to provide treatment outpatient or inpatient treatment for CAP is 
extremely important, however admission rates for patients with CAP vary 
significantly (Lim et al., 2003).  The two previously mentioned prediction rules are 
used to help in this selection process.  The PSI assigns points to patients on the 
basis of 20 different variables and then assigns patients to 1 of 5 risk classes on the 
basis of the points calculated (Fine et al., 1997).  Usually, patients that fall within 
class I–III receive treatment and clinical management as outpatients, whereas those 
that fall in classes IV and V are generally hospitalised.  
 
CURB-65 is an acronym and represents a point scale based on confusion, urea 
level, respiratory rate, breaths/min, low systolic or diastolic blood pressure, and age. 
Patients with a score of 0 or 1 receive treatment as outpatients, those with a score of 
2 receive treatment in a non- ICU hospital ward, and those with scores of >3 may 
require admission to the ICU. 
 
30 
 
 
 
However, few studies have assessed the independent effect of the microbial 
aetiology on PSI and CURB-65 severity scores (Roson et al., 2001).  One notable 
study aimed to investigate the distribution of the aetiology according to a specific 
clinical setting and severity scores (PSI and CURB-65) and the relative mortality 
rates in a large series of patients with CAP (Cillóniz et al., 2011).  The performance 
of CURB-65 in predicting mortality in community-acquired pneumonia (CAP) has 
been tested in two large observational studies in patients with sepsis and 
implementation of warning scores, for identification of high-risk patients in acute 
medical wards (Barlow et al., 2007).  
 
In the United Kingdom, the BTS guidelines promote the use of CURB-65.  This tool, 
proved to have 75% sensitivity and 75% specificity at predicting mortality at 30 days 
in CAP.  This was a large prospective multicentre, multinational study (Lim et al., 
2003). 
 
In another study, PSI and CURB-65 assessments performed similarly in predicting 
the 28-day and in-hospital mortality; however; there was a significant mortality in 
patients with a CURB-65 <3 and PSI <5 whilst differences in the categorisation of 
severe CAP were noted (Richards et al., 2011). 
  
A large amount of CAP research has been dedicated to comparing the various 
assessment systems to try and identify which is the most reliable system.  In 
general, all of the previously mentioned systems have limitations, particularly in 
younger patients, and cannot replace a reliable clinical decision.  The results depend 
on the use to which each system is being put (e.g. inpatient vs. outpatient 
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management, the requirement of an intensive care bed, or predicting morbidity or 
mortality, etc.), the particular institution to which it is applied and the severity of CAP 
of the cohort studied (Waterer et al., 2011).  
 
1.7 Microbiological diagnostics 
There is little evidence to suggest that microbial investigation affects mortality, but 
serves as a guide to antibiotic use as well as providing information for 
epidemiological purposes (Armitage and Woodhead, 2007).  Controversy still exists 
over sputum Gram stain reporting.  Some guidelines recommend that Gram stains of 
sputa prior to culture are useful to expand antimicrobial coverage (Lévy et al., 1988) 
but others recommended positive results as a guide to narrow the therapeutic 
antimicrobial spectrum (Gleckman et al., 1988).  In addition, 5 to 38% of CAP cases 
are due to mixed organisms (Brown et al., 1986).  Therefore, Gram staining results 
should be considered when interpreting the significance of sputum cultures (Gross et 
al., 2003).  
 
All sputum investigations are dependent on the quality of the specimen (Bartlett 
2011).  The premises of the Gram stain according to the Bartlett score are that 
neutrophils indicate infection/inflammation and squamous epithelial cells suggest 
contamination.  Gram stains of the specimen are read at low magnification (x100) 
and are scored 0, +1, or +2 according to the number of neutrophils seen per field 
and 0, -1, and -2 according to the number of squamous epithelial cells seen per field. 
Specimens with a zero or less score are considered inadequate (Bartlett 1974). 
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Those containing more than 25 neutrophils and fewer than 10 squamous epithelial 
cells per field are optimal specimens. 
 
Except for the Japanese Respiratory Society (JRS), all societies recommend that 
two sets of blood cultures be taken from all patients admitted to hospital with 
pneumonia, preferably before the administration of antibiotics (Macfarlane and 
Boldy, 2004).  The JRS only recommend this in cases of severe pneumonia 
(Miyashita et al., 2006).  
 
Routine serological investigation for urinary antigen testing for Legionella 
pneumophila and Streptococcus pneumoniae are only recommended in severe 
cases (Woodhead and Macfarlane, 1987).  Serological testing may be useful during 
outbreaks for epidemiological investigations, but with no impact on clinical 
management.  Despite more than a century of microbiological tests, there is still 
uncertainty about the actual importance of the various organisms that cause 
pneumonia.  The most important reason for this is the difficulty in obtaining samples 
directly from lung tissue.  Lung biopsy and other invasive procedures can be used in 
very few selected patients that are hospitalised.  Microbiological cultures of blood 
yield results for only 4%–24% of patients that are hospitalised (Sullivan et al., 1972) 
and <1% of patients that are being managed as outpatients (Woodhead and 
Macfarlane, 1987). 
 
Numerous indirect microbiological methods may be better suited for patients with 
CAP.  Currently, some clinicians rely mainly on microscopy (Gram stain) and culture 
of sputum with a good Bartlett score to determine bacterial aetiology (Mundy et al., 
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1995).  One could also exclude sputum findings for fear of interpreting a 
contaminated result and treating is as the aetiological agent (Bates et al., 1992). 
Others also look for bacterial antigen in sputum, serum, or urine (Ortqvist et al., 
1990), a serum antibody response (Lieberman et al., 1996), or pneumococcal 
immune complexes in serum (Liebermann et al., 1996).  Despite validation of these 
methods, none have predicted true microbial aetiology of CAP due to the lack of a 
well-defined reference standard.  
 
In contrast, methods to determine viral aetiology, including serological methods, are 
more widely accepted.  Conventional diagnostic tests of respiratory tract samples 
have low diagnostic yield.  
 
1.8 Collection and detection methods 
The collection and transport of clinical specimens to the microbiology laboratory is 
important as the first step in diagnostic testing.  Apart from the nucleic acid test used 
or different RNA/DNA extraction protocol, specimen collection, specifically the 
inactivation of potentially infectious agents and the preservation and stability of 
pathogen RNA/DNA remains a critical gap in clinical diagnostics.  It is important to 
note that the nasopharyngeal detection swabs are not of equal quality (Sautter and 
Wilson, l988). 
 
The ability to recover organisms from swabs used for specimen collection is critical 
for the laboratory diagnosis of aetiological agents of CAP.  It has to be considered 
that approximately 10-15% of the organisms collected on traditional spun fibre swabs 
can be recovered from cultures, as well as by nucleic acid amplification (Moore-Ness 
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and Sautter, 2004).  Dacron or rayon flexible nasopharyngeal swab collected during 
the acute phase of illness is the single best test method for demonstrating current 
viral infection.  
 
Nylon flocked swabs composed of open nylon fibres potentially release a much 
higher yield of viable organisms.  The flocked swab traps bacteria by capillary action 
whereas traditional swabs absorb bacteria onto the surface of the cotton fibers 
thereby trapping them within the fiber matrix.  Physical properties are commonly 
evaluated such as the ability to absorb clinical material from the site of infection, the 
potential to maintain viability of organisms during transport and the ability to release 
the material onto the agar surface prior to culturing. 
 
A single nasopharyngeal swab performed moderately well in the detection of 
Streptococcus pneumoniae carriage, and the additional yield with two swabs was not 
sufficiently high upon culturing (Brugger et al., 2009).  The low sensitivity of 
nasopharyngeal swab cultures needs to be considered into the interpretation of CAP 
studies.  
 
The collection system, PrimeStore™ MTM, inactivates microbes from clinical 
specimens and prevents nucleic acid degradation during shipping and storage 
(Daum et al., 2008).  It is temperature stable and suitable for outbreak surveillance.  
The pathogen specific detection system, PrimeMix, is an all inclusive, one-step PCR 
reagent mix for point of collection detection.  
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PrimeStore™ MTM formulation preserves and stabilises RNA/DNA in a wide range 
of sample matrices including nasal/throat swabs, nasal aspirates, culture and other 
biological specimens (Daum et al., 2007).  PrimeStore™ MTM maintains RNA 
stability and preservation compared to other storage and transportation media.  
Using PrimeStore™ MTM, users can accurately quantify viral loads in samples 
stored under conditions that would significantly degrade RNA in alternative 
preservation solutions (Daum et al., 2008). 
 
Specimens collected in PrimeStore™ MTM can be transported at ambient 
temperature without cold-chain shipping.  Additionally, cells and microbes from 
collected specimens are lysed and killed (Daum et al., 2008).  PrimeStore™ MTM is 
compatible with most commercial extraction systems(silica and bead-based) for 
nucleic acid isolation such as Qiagen and Life Technologies systems.  PrimeStore™ 
MTM includes an internal positive control (IPC) that provides a built in measure of 
specimen integrity and serves as a carrier species for increasing the DNA and RNA 
extraction efficiency from samples with few copies.  PrimeMix is one-step, real-time 
PCR blend formulated and optimised as a ready use solution that does not require 
additional ‘mastermix’ preparation.  It is rapid (about 1 hr from collection to 
detection), and is stable from days to weeks if refrigerated, and months if frozen 
(Daum et al., 2007). 
 
1.9   Molecular diagnostics 
Nucleic acid detection with the use of real-time polymerase chain reaction (PCR) has 
been developed for many bacterial and viral pathogens causing respiratory tract 
infections (Welti et al., 2003). 
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Conventional microbiological assays for detection of bacterial and viral respiratory 
tract pathogens have proven to be slow, insensitive, unable to strongly distinguish 
between infection and colonization, and the yield is heavily decreased by 
introduction of antibiotic treatment prior to collection of relevant specimens. 
Molecular diagnostic assays for bacteria and atypical pathogens of community 
acquired pneumonia have the potential to significantly improve the diagnostic yield 
and decrease turnaround time required for accurate results.  Due to various reasons, 
these tests often lack standardisation and are not widely available.  Consideration 
should be given to the development and evaluation of companion molecular 
diagnostic tests for detection of respiratory pathogens in future clinical trials of 
antimicrobials intended to treat community-acquired pneumonia (Nolte, 2008). 
 
 One of the advantages of molecular diagnostics is the possibility of identifying 
pathogens in patients already receiving antibiotic treatment.  Some of these new 
PCR methods have been evaluated concurrently in a prospective study of patients 
with CAP (Kais et al., 2006) as prior antimicrobial treatment is an important factor 
which decreases the diagnostic yield in traditional culture based methods.  In a large 
series, no diagnosis was made in 45% of the cases (Fang et al., 1990). 
Molecular diagnostics undertake detection of the common and atypical bacterial 
pathogens that cause CAP.  Analysis can be completed in hours, rather than days, 
for detection of typical pathogens and weeks for detection of atypical pathogens. 
This approach eliminates concerns about decreased organism viability associated 
with transport of specimens and the effects of previous antibiotic therapy.  Real-time 
PCR panels that include the common causative pathogens of CAP could 
substantially increase the diagnostic yield in clinical practice.  However, molecular 
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platforms in this setting are not validated or standardised or widely available.  
Currently, these assays will supplement culture-based methods for organisms for 
which antibiotic sensitivity is of concern.  
Molecular assays provide high levels of automation, are less labor intensive, and 
have sensitivities and specificities quite comparable to those of culture-based 
methods and are cost effective in the long run.  Their potential value is that they can 
expand the expertise of routine microbiological and virological laboratories to 
increase their detection of viral and bacterial pathogens previously poorly identified, 
such as rhinoviruses, coronaviruses, and Streptococcus pneumoniae (Oosterheert et 
al., 2005).  A higher diagnostic yield for respiratory pathogens could improve 
management of CAP but may not decrease antibiotic use, length of hospitalisation, 
or treatment expenses (Oosterheert et al., 2005). 
One drawback of PCR-based assays to diagnose PCP is the detection of low levels 
of organisms that might actually represent colonization and not active infection 
(Larsen et al., 2004). 
 
1.10 Rationale for study  
There are numerous reasons for better understanding of the aetiology of CAP.  
Knowledge of the microbial or viral pathogen in question allows for the use of 
antibiotics with a narrower-spectrum of activity that will in turn be directed towards a 
specific microorganism.  This approach would limit the use of broad-spectrum 
antibiotics, avoid antibiotic-related selection pressure and decrease or impede the 
development of resistance.  Early initiation of antimicrobial therapy is important in the 
management of severe CAP. 
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Geographic variability is an important factor in the epidemiology of CAP.   It requires 
periodic surveys in multiple areas and is essential to increase background 
knowledge with regards to the aetiology of CAP.   
 
By collecting information on the various aetiological pathogens responsible for CAP 
in a particular region and information on their susceptibility patterns, we provide 
useful background reference for the management of individual cases and to national 
treatment guidelines.  Definitive knowledge of the aetiological pathogen enhances 
the capacity of the clinician to interpret CAP whether it is to de-escalate empiric 
therapy or withdraw antibiotics if a viral organism is the aetiological pathogen.  Risk 
factors for specific pathogens and risk factors for antimicrobial resistance often 
overlap, and there are no definitive data linking risk factors for pathogens or 
resistance to prognosis. 
 
It is interesting to note that Ewig et al., (2002) reported 82 of 204 (40%) patients with 
CAP without an aetiological agent, despite a substantial diagnostic effort.  A 
multivariable analysis revealed age, renal and cardiac co-morbidity, and non-alveolar 
radiological pattern as independent risk factors for an unknown aetiology.  Oddly, 
mortality was not different between patients with and without an aetiology for CAP 
(Ewig et al., 2002).  An interesting confounder, which may have accounted for the 
number of undiagnosed cases, is incomplete diagnostic work-up.  The greatest 
limitation in the performance of microbiological research is the lack of sensitivity and 
specificity of current routine diagnostic methods.  An extensively broad and fully 
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encompassing aggressive diagnostic approach may have affected the diagnostic 
yield. 
 
The aim of the present study was to investigate the aetiology of all bacterial and viral 
cases of community-acquired pneumonia that occurred in the adult patients that 
were admitted to the hospital.  The study also assessed the incidence of mixed 
infections, by utilising a new diagnostic PCR platform in addition to conventional 
microbiological methods.   The confounding factor of antimicrobial pretreatment and 
co-infection with tuberculosis was excluded. 
 
1.11 Study Objectives 
1.11.1 Primary 
The aim of the study was to describe the microbial aetiology of CAP in adults 
presenting to an urban tertiary-care hospital in Gauteng, South Africa. 
1.11.2 Secondary 
To determine by PCR detection the DNA/RNA preserved/ stabilized in PrimeStore™ 
MTM from nasopharyngeal swabs from patients that met the inclusion criteria of the 
study prior to their first dose of antibiotics.  Samples collected by PrimeStore™ MTM 
were stored at room temperature for up to 72 hours until they were processed by 
PCR.  
1.11.3 Design 
This was a prospective, descriptive, clinical and microbiological investigational study. 
1.11.4 Study site 
This study was performed at the Charlotte Maxeke Johannesburg Academic 
Hospital, in South Africa.  Acutely ill patients were enrolled as they were admitted to 
40 
 
 
 
the casualty, and thereafter to the infectious diseases ward or other medical wards at 
the hospital.  The site of care of each patient was recorded post admission.  Patient 
enrollment was sequentially begun at the beginning of June 2010 and completed at 
the end of November 2010 
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CHAPTER 2: MATERIALS AND METHODS 
2.1 Definitions 
2.1.1 Community Acquired Pneumonia 
Refers to a lower respiratory tract infection not acquired at a hospital or a long-term 
care facility.  Pneumonia is an acute infection of the lung parenchyma associated 
with clinical and radiological evidence (Feldman et al., 1995).  
2.1.2 CAP in a community setting 
Refers to a complex of symptoms of sweating, fevers, shivers, aches, pains and/or 
temperature of 38°C with symptoms of an acute lower  respiratory tract illness (for 
example coughing) and new focal chest signs on examination (Lim et al., 2009). 
2.1.3 CAP in patients admitted to hospital (mandatory chest x-ray). 
Acute lower respiratory tract infection associated with signs and symptoms that 
correlate with radiological changes for which there is no other explanation.  This 
disease episode is the primary reason for hospitalisation (Lim et al. 2009). 
2.1.4 “Definite” aetiology of CAP 
A pathogen is generally considered to be of definite aetiological significance if it is 
cultured from blood or if the urine antigen assay for Legionella pneumophila is 
positive (Kalin, 1982). 
2.1.5 “Probable” aetiology of CAP 
The identification of an organism in sputum culture is accepted to be of probable 
significance (Kalin, 1982).   A viral or bacterial aetiology is deemed probable if 
detection by reverse transcriptase PCR testing for respiratory viruses and PCR for 
any bacteria is positive. 
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2.1.6 “Possible” aetiology of CAP 
The concept of a “possible” aetiology is based on novel adopted clinical practices for 
the interpretation of a positive (1→3)-β-D-glucan > 500 as well as a radiological 
picture of PJP which is suggestive of a fungal aetiology of Pneumocystis jivorecii 
pneumonia.  
 
2.2 Sample population  
A total number of 104 patients were screened for the study and 48 patients met the 
inclusion criteria.  The aim was for a sample size of 50 patients but the strict 
inclusion criteria as well as the cost of materials were limiting factors that affected 
the final sample size.  
 
2.3 Patient selection 
Both male and female adult patients (age ≥ 18 years) with CAP who were examined 
or admitted to the Charlotte Maxeke Johannesburg Academic Hospital were 
screened for the study.  Patients were informed about the study, and those who gave 
written informed consent were then further screened according to inclusion criteria 
based on clinical and radiological grounds.  Subsequently, a questionnaire and case 
report form was completed for each patient.  
 
Ethical approval was obtained from the University of Witwatersrand, Human 
Research Ethics Committee/R14/49 (Appendix 5).  The study details were discussed 
and a written information sheet (Appendix 2) handed out to all participants prior to 
obtaining written informed consent (Appendix 1).  A clinical data sheet (Appendix 2) 
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was used to record all relevant clinical details.  Study participation did not disrupt the 
participants’ routine diagnostic work-up. 
The Charlotte Maxeke Johannesburg Academic Hospital is an accredited central 
hospital with 1088 beds serving patients from across the Gauteng province and 
neighboring provinces.  The hospital offers a full range of tertiary, secondary and 
highly specialised services.  The hospital is located in Parktown and serves as a 
referral hospital for a number of hospitals in its referral chain.  No walk-in patients 
are seen.  All patients need to be referred via a medical practitioner, clinic or hospital 
within the referral system.  
2.4 Diagnosis of CAP 
All patients were assessed by an infectious disease clinician to confirm whether they 
met the inclusion criteria: 
A) Radiological changes consistent with CAP and two or more of the following signs 
or symptoms:  
1. On admission: 
a. Medical history of productive cough with sputum production with or without 
pleuritic chest pain (not more than a five day history).  
b. Physical examination on day of admission in casualty 
i. Vital signs 
1. Fever >38 ºC or Hypothermia <35 ºC 
2. Confusion/cyanosis 
3. Tachypnoea (>20 breaths per minute) 
4. Blood pressure (<90/60 mmHg) 
ii. Chest examination 
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1. Dullness to percussion 
2. Decreased breath sounds  
3. Bronchial breathing  
4. Crepitations 
c. Laboratory 
1. Leukocytosis (>12 000 cells/mL) 
2. Leukopenia (<4000 cells/mL) 
3. Urea >7 mg/dL 
4. HIV (optional on clinician request- this wasn’t an exclusion criteria) 
5. (1→3)-β-d-glucan serum level if clinically indicated 
6. Streptococcus pneumoniae serotyping (if blood culture positive) 
7. CURB-65 scoring system (confusion, urea>7mg/dL, respiratory rate more 
than 30 breaths/min, blood pressure 90/60 mmHg and age above 65 years 
was used to determine severity of pneumonia and admission to the wards 
or the ICU.  
2. Radiological findings as per criteria in Appendix 2   
2.5 Exclusion criteria 
a. Lack of consent 
b. Age <18 years 
c. Cystic fibrosis patients 
d. Patients with suspected tuberculosis: 
i. Presence of cavitatory lung disease based on chest x-ray at admission and 
or, 
ii. Presence of acid fast bacilli on sputum microscopy confirmed within 24 
hours of current admission. 
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e. Patients on tuberculosis treatment. 
f. Patients transferred from other hospitals with symptoms of pneumonia. 
g. Patients re-admitted within 2 weeks of previous admission.  
h. Resident of long-term care facility such as old age homes, or other similar 
institutions.  
i. Antibiotic use within the previous 48 hrs (from patient history). 
A full clinical and radiological assessment was done at the bedside and recorded on 
the patient data sheet.  All additional routine laboratory testing, as requested by the 
attending physician was also recorded.  
 
2.6 Microbiological specimen collection and testing  
2.6.1. Sputum microscopy, culture and sensitivity 
Patients were given instruction on how to produce a deep cough specimen of 
sputum.  They were asked to cough forcefully and spit out sputum into a container.  
Five milliliters of expectorated sputum was collected in a sterile container and 
submitted for microbiological diagnosis.  Sputum was collected before antibiotic 
administration and submitted to the microbiology laboratory for microscopy.  
Samples containing neutrophils and a limited number of squamous epithelial cells 
were considered acceptable for culture, according to the established criteria of a 
Bartlett score greater than zero (Bartlett 1974).  Antibiotic susceptibilities were 
determined for Streptococcus pneumoniae and Haemophilus influenzae.   The 
minimum inhibitory concentration (this is the lowest concentration of an antimicrobial 
that will inhibit the growth of an organism) of penicillin in Streptococcus pneumoniae 
was determined according to guidelines of a reference body, Clinical Laboratory 
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Standards Institute (CLSI, 2010).  A sputum immunofluorescence assay was used to 
determine the presence of Pneumocystis jirovecii.   
2.6.2 Nasopharyngeal swab  
Nasopharyngeal swabs were collected and stored in the PrimeStore™ MTM  for 
PCR testing of typical and atypical bacterial organisms: Streptococcus pneumoniae, 
Haemophilus influenzae, Mycoplasma pneumoniae, Chlamydophila pneumoniae, 
Bordetella pertussis and Legionella pneumophila as well as the following respiratory 
viruses; adenovirus;  influenza A virus; influenza B virus; respiratory syncytial virus 
A; respiratory syncytial virus B; metapneumovirus; parainfluenzavirus 1, 2 and 3;  
rhinovirus A/B; coronavirus 229E/NL63, coronavirus OC43/HKU1and bocavirus. 
 
2.6.3 Sputum auramine stain 
Another sterile container was used to collect sputum for a fluorescent auramine stain 
to exclude the presence of AFB (acid-fast bacilli) as it was an exclusion criterion.  
 
2.6.4 Blood cultures  
Blood for culture and bacterial identification was collected.  Blood was obtained by 
inserting a needle into a vein in the arm.  The drawing site was thoroughly cleaned, 
usually with an isopropyl alcohol solution, applied in a circular pattern and then 
allowed to dry.  The phlebotomist drew about 20 milliliters of blood and put it into two 
culture bottles containing broth.  These two bottles constitute one blood culture set.  
The sample was sent for routine bacterial culture, identification and susceptibility 
testing. 
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2.6.5 Urine antigen  
Urine samples for Legionella pneumophila testing were collected and an 
immunochromatographic membrane test (BinaxNOW Legionella; Inverness Medical 
Innovations) was performed on urine samples for detection of Legionella 
pneumophila serogroup 1 antigen within 24 hours of collection. 
 
2.6.6 (1→3)-β-D-glucan (BDG) 
Serum samples were collected from patients with a clinical and radiological picture of 
PJP.   
 
2.6.7 HIV status 
HIV antibody testing was performed on clinical grounds at the discretion of the 
attending clinician following consent from the patient. 
 
2.6.8 Streptococcus pneumoniae serotyping 
Streptococcus pneumoniae isolates from blood were sent to the Respiratory and 
Meningeal Pathogens Research Unit at the National Institute for Communicable 
Diseases (The Group for Enteric, Respiratory and Meningeal disease Surveillance in 
South Africa (GERMS-SA)) to undergo Neufeld’s Quellung reaction (Lalitha et al., 
1996).  The high cost and the demanding technical expertise required for this 
reaction prohibit the adoption of this method for regular serotyping in a routine 
laboratory. 
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2.7   Molecular methods 
The Seeplex RV5 ACE screening for the detection of adenovirus; influenza A virus; 
influenza B virus; respiratory syncytial virus A; respiratory syncytial virus B; 
metapneumovirus; parainfluenzavirus 1, 2 and 3; rhinovirus A/B; coronavirus 
229E/NL63; coronavirus OC43/HKU1 and bocavirus was used. 
 
The second kit utilised for the detection of Streptococcus pneumoniae, Haemophilus 
influenzae, Mycoplasma pneumoniae, Chlamydophila pneumoniae, Bordetella 
pertussis and Legionella pneumophila was called the Seeplex Pneumobacter 
multiplex PCR kit.  
 
2.8 Diagnosis of aetiology 
 The diagnosis of CAP is conventionally defined as signs and/or symptoms 
compatible with a respiratory tract infection in the presence of new consolidation on 
a chest radiograph.  The chest radiograph is the gold standard (Hedlund et al., 
2005).  A pathogen was considered to be of definite aetiological significance if it was 
cultured from blood, or if the urine antigen assay for Legionella pneumophila was 
positive.  Detection of Legionella pneumophila by PCR from nasopharyngeal swab 
was also considered as definite support for the aetiology. 
 
In accordance with previous findings of patients with bacteremic pneumococcal 
pneumonia, identification of Streptococcus pneumoniae in sputum culture was 
accepted to be of probable significance (Kalin, 1982).  A viral or bacterial aetiology 
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was deemed probable if detection by reverse transcriptase (RT)-PCR testing for 
respiratory viruses and PCR for any bacteria was confirmed. 
 
2.9 Clinical data collection and analysis 
Each patient's medical records were reviewed for clinical data. This descriptive study 
employed simple statistical analysis including mean, percentage, and correlation 
between variables. Interviews with the patients or next of kin provided an opportunity 
to follow a line of questioning that obtained more in-depth information. 
The study required little interference on the part of the observer other than routine 
clinical practices as well as the nasopharyngeal swabbing.  Data collection sheets 
involved recording and timing the events observed, transcribing data into coding 
sheets and thereafter transferring data from the coding sheets onto a database for 
data analysis.  Data was aggregated, interpreted according to inclusion criteria and 
thereafter analysed to produce a variety of graphic data representations.   
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CHAPTER 3: RESULTS 
 
3.1 Patient demographics  
The baseline characteristics of the patients are shown in the table 3.1.  The study 
population consisted of 20 males and 28 females.  The mean age for males was 
43.9 years and the mean age for females was 36.3 years.  A total of 48 patients had 
at least one underlying disease, with HIV infection being the highest co morbidity 
(60.4%).  Five patients were confirmed smokers.  The other co-morbidites included 
five patients with chronic obstructive pulmonary disease (COPD), two asthmatic 
patients, three patients in cardiac failure, one patient in liver failure, three patients 
with diabetes mellitus type II and five patients with confirmed alcohol use.   
 
The mean duration of stay in hospital was 5.1 days (range, 1–6.9 days).  None of the 
48 patients came from a rural background or had resided in a rural area in the past 
year nor did they have any prior mining employment history.  All 48 patients had 
access to running water and electricity. 
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Table 3.1 Patient Demographics 
Demographic Data % (No.) 
N 48 
Males 41.7% (20) 
Females 58.3% (28) 
Mean Age 39.5 years 
Males 43.9 years 
Females 36.3 years 
Smoking 10.4%(5) 
Site of Care  
General pulmonology ward 68.7% (33) 
Intensive care unit 31.2% (15) 
Co-morbidity  
HIV 60.4% (29) 
COPD 10.4% (5) 
Asthmatic 4.1% (2) 
Cardiac failure 6.2% (3) 
Liver failure 2.0% (1) 
Diabetes mellitus 6.2% (3) 
Alcohol abuse 10.4% (5) 
Symptoms  
Productive coughing 85.4% (41) 
Fever  60.5% (34) 
Confusion 12.5% (6) 
Pleuritic chest pain 14.5% (7) 
Radiologic appearance  
Consolidation 62.5% (30) 
Pleural effusion 14.5% (7) 
Reticular infiltrate 12.5% (6.0) 
Ground glass appearance 10.4% (5.0) 
 
Negative Urine Leg. Antigen 
 
100% (48.0) 
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3.2 Bacterial and viral aetiology as determined by different diagnostic methods 
The contribution of the different methods in the determination of aetiology is 
illustrated by the distribution of 80 pathogens among 48 patients (table 3.2).  Blood 
cultures provided a definite aetiology for 8 (16.7%) of 48 patients. A probable 
diagnosis was established by sputum culture alone for 5 (10.4%) of 48 patients.  This 
probable aetiology increased (as defined previously) when a molecular PCR platform 
was added to the conventional methods with the use of the PrimeStore™ MTM 
swabs to 62.5% (30 of the 48 patients).  
 
The most frequently detected bacteria across all assays was Streptococcus 
pneumoniae (23 times in total) and Haemophilus influenzae (14 times in total). 
Human metapneumovirus, rhinovirus A/B and coronovirus were the most frequently 
detected viruses (8 times in total or each).  Only 4 of those 8 instances had those 
viruses as probable mono-viral aetiology (blood cultures, sputum cultures and 
bacterial PCR negative).   
 
There were five patients in whom an aetiological pathogen was never ascertained. 
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Table 3.2 Bacterial and viral aetiology as determined by different diagnostic 
methods 
 
PATHOGEN 
 
FREQUEN
CY OF 
POSITIVE 
FINDINGS 
 
 
POSITIVE 
BLOOD 
CULTURE 
 
POSITIVE 
SPUTUM 
CULTURE 
 
POSITIVE PCR 
NASOPHARYNGEAL 
SECRETION SAMPLE 
(DNA) 
 
POSITIVE PCR 
NASOPHARYNGEAL 
SECRETION 
SAMPLE (RNA) 
S. pneumoniae 23 8 4 20 N/A 
H. influenzae 14 0 3 14 N/A 
Metapneumovirus 8 N/A N/A N/A 8 * 
Rhinovirus A/B 8 N/A N/A N/A 8 * 
Coronavirus 
229E/NL63/ 
OC43/HKU1 
 
8 
 
N/A 
 
N/A 
 
N/A 
 
8 * 
Influenza A  6 N/A N/A N/A 6 
Adenovirus 3 N/A N/A N/A 3 
Influenza B  1 N/A N/A N/A 1 
Respiratory 
Syncytial virusA/B 
 
1 
 
N/A 
 
N/A 
 
N/A 
 
1 
Parainfluenza1,2,3 1 N/A N/A N/A 1 
M. pneumoniae 1 0 0 1 N/A 
Bocavirus 1 N/A N/A N/A 1 
S. pneumoniae 
and H. influenzae 
co-infection 
 
8 
 
3** 
 
2*** 
 
8 
 
3**** 
Negative PCR and 
negative cultures 
but BDG>500 
 
 
5***** 
 
 
N/A 
 
 
N/A 
 
 
N/A 
 
 
N/A 
(REPRESENTING THE DISTRIBUTION OF 80 PATHOGENS AMONG 48 PATIENTS) 
NOTE: All urine L. pneumophila Serogroup 1 antigen tests were negative 
*All 3 bands appeared together in all 8 positive samples.   
 ** In these 3 cases blood culture only yielded S.pneumoniae.  H.influenzae was not cultured. 
*** In these 2 cases sputum culture only yielded S. pneumoniae.  H. influenzae was not cultured. 
**** Case #1 had a viral co-infection with influenza B. Blood culture positive S. pneumoniae only.   
Sputum culture neg. Case #2 had a viral co-infection with Adenovirus and influenza A. No positive 
bacterial cultures despite positive Pneumobacter. Case #3 had a viral co-infection with Influenza A. 
Blood culture positive S. pneumoniae and sputum culture negative. 
***** Only 1 case positive by monoclonobal antibody assay for Pneumocystis jirovecii pneumonia 
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3.3 Microbial aetiology of CAP 
A total probable microbial aetiology (as defined previously) of CAP was established 
for 62.5% (30 of the 48 patients) when the PCR platform for respiratory viruses was 
added to the conventional methods with the use of the PrimeStore™ MTM swabs 
(table 3.3).  In contrast, the definite bacterial aetiology was 16.7% (8 of 48 patients) 
when conventional culture methods were used, none of whom had more than one 
bacterial species identified.  There were five patients in whom an aetiological 
pathogen was never ascertained.  The urine Legionella pneumophila antigen was 
negative for every single patient.  Of the 16.7% of patients with a definite bacterial 
aetiology Streptococcus pneumoniae was isolated from blood cultures in all patients 
(table 3.3). 
 
There were five patients in whom blood cultures and sputum cultures were negative 
but the clinical and radiological reporting was indicative of PJP with a positive (1→3)-
β-d-glucan >500.  For this group of patients the term possible aetiology was 
introduced and these patients were categorised as such.   
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Table 3.3 Microbial aetiology of CAP 
 
PROBABLE  
MICROBIAL AETIOLOGY 
 
 
DEFINITE  
BACTERIAL AETIOLOGY 
 
 
POSSIBLE  
AETIOLOGY 
 
62.5% (30) 
 
 
 
16.7% (8) 
 
 
 
 
 
 
10.4% (5) 
 
 
SPUTUM CULTURE 
 
MOLECULAR 
 
10.4%(5) 
 
52.1% (25) 
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A probable aetiology was ascertained in 5 patients with positive sputum cultures.  All 
5 sputum cultures yielded the same isolates when bacterial PCR was undertaken.  
Streptococcus pneumoniae was cultured in 3 of those patients on their sputum and 
thereafter confirmed on PCR.  The other 2 patients cultured Haemophilus influenzae 
on sputum that was confirmed by PCR.  One of these patients also had three viral 
bands representing metapneumovirus, human rhinovirus virus and coronavirus and 
the second patient was co-infected with respiratory syncitial virus A/B. 
 
An additional 25 patients (in whom sputum and blood culture was negative) had a 
probable aetiology attributed to their CAP with positive PCR results.  The PCR was 
positive for five patients with both Streptococcus pneumoniae and Haemophilus 
influenzae.  Three of these five patients also had a positive viral PCR.  The first one 
had a positive influenza B band, the second one was co-infected with adenovirus 
and influenza A and the third patient had a positive band for influenza A.  The 
remaining two patients had a positive PCR with the previously mentioned dual 
bacteria only. 
 
 The PCR was positive for Streptococcus pneumoniae for 8 patients in whom 
sputum, blood cultures and viral PCR were negative (figure 3.3.1). 
 
Haemophilus influenza PCR was positive in 3 patients in whom sputum and blood 
cultures were negative.  Two of these patients were also negative for the viral PCR.  
One of these 3 patients had positive bands for human metapneumovirus, rhinovirus, 
coronaviruses and influenza A. 
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                Figure 3.3.1 Bacterial Aetiology
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There were nine patients with positive viral PCR’s only that were representative of 
probable CAP aetiologies.  From this group of patients, four of them were positive for 
metapneumovirus, rhinovirus and coronaviruses, three were positive for influenza A 
and one patient was positive for adenovirus, parainfluenzae virus and bocavirus.  
The last patient was positive for adenovirus but also had signs indicative of PJP with 
a BDG>500.  
 
There were five patients in whom blood cultures and sputum cultures had negative 
tests for other pathogens but the clinical and radiological reporting was indicative of 
PJP with a positive BDG>500.  Out of these 5 positive BDG’s only 1 of these patients 
had a positive immuno-fluorescence assay.  One had a mixed infection with a 
positive BDG and a positive PCR for Mycoplasma pneumoniae.  Another one of 
these patients, was a patient mentioned earlier with a positive viral PCR for 
adenovirus who was also admitted to the intensive care unit and intubated.   
 
Figure 3.3.2 depicts the range of total patients’ viral pathogens detected as probable 
viral aetiology. 
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          Figure 3.3.2 Probable Viral Aetiology
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3.4 Microbial aetiology in the Intensive Care Unit. 
 Of the 48 patients, five were transferred directly to the intensive care unit from 
casualty and a further 10 were transferred within 48 hours of admission.  An 
aetiological agent was found in the samples of 12 of these 15 patients (figure 3.4.1). 
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Figure 3.4.1 Definite, Probable & Possible Aetiology for patients admitted to ICU
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Eight patients had definite Streptococcus pneumoniae as the aetiology of CAP 
based on positive blood cultures (table 3.4.2).  For two of these eight patients, viral 
PCR was positive for metapneumovirus, rhinovirus and coronavirus as co-
pathogens.   Bacterial PCR confirmation of Streptococcus pneumoniae correlated 
with another three of these eight definite cases.  Another two of these eight patients 
with positive Streptococcus pneumoniae blood cultures had positive bacterial PCR’s 
for the Streptococcus pneumoniae and Haemophilus influenza as well as positive 
viral PCR’s representing influenza B for the first case and influenza A for the second 
case.  The last patient in this group was only blood culture positive for Streptococcus 
pneumoniae.   
 
In the probable aetiology group of admissions in ICU, two patients were positive for 
Haemophilus influenza PCR but were negative for blood cultures and sputum 
cultures.  For one of these two patients, metapneumovirus, rhinovirus and 
coronavirus were also detected.  The second patient also had a positive 
Streptococcus pneumoniae PCR.   
 
One of the 12 patients admitted to the ICU had a positive PCR for influenza A.   
 
The three patients without a known aetiological agent presented severely 
tachypnoeic, BDG>500 (positive) with their chest x-rays suggestive of PJP.  Only 
one of these three patients had a positive PJP immuno-fluorescence assay. Another 
one of these three patients had a positive viral PCR for adenovirus. 
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Figure 3.4.2 Microbial Aetiology of patients admitted to ICU
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3.5. Streptococcus pneumoniae serotypes  
All eight-blood culture confirmed Streptococcus pneumoniae isolates were from 
patients admitted to ICU.  The serotypes identified were 1, 4, 9N and 19A as 
summarised in table 3.4.  One isolate was missing from the NICD serotyping 
database.  The clinical features of bacteraemic pneumococcal pneumonia were 
similar in HIV-seropositive (5) and HIV-seronegative (3) patients.  All 5 HIV-
seropositive patients had underlying risk factors other than HIV infection that may 
have predisposed them to pneumococcal bacteraemia.  These underlying risk 
factors included the following: diabetes mellitus, chronic pancreatitis secondary to 
alcohol consumption, COPD and cardiac failure.  The predisposing co-morbid factors 
in the 3 HIV negative patients were COPD, diabetes mellitus and cardiac failure. 
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Table 3.4 Serotype distribution and penicillin minimum inhibitory concentrations (MIC) of Streptococcus pneumoniae 
isolates from blood cultures. 
 
SEROTYPE 
 
N = 8 
 
ICU 
 
PENICILLIN MIC (µg/ml) 
 
 
9N 
 
1 
 
1 
 
0.38 
 
8 
 
1 
 
1 
 
0.008 
 
1 
 
1 
 
1 
 
0.38 
 
19A 
 
3 
 
3 
 
0.38(all 3) 
 
4 
 
1 
 
1 
 
0.5 
 
MISSING ISOLATE 
 
1 
 
1 
 
0.5 
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3.6 Microbial aetiology based on severity of CURB-65 score 
The most common pathogen was Streptococcus pneumoniae.  The frequency of 
other pathogens decreased with severity (figure 3.6.1).  Streptococcus pneumoniae 
was also noted to be the most common pathogen for the two extremes of the CURB-
65 scores (figure 3.6.2).  
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  Figure 3.6.1 Microbial Aetiology Based on Severity 
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       Figure 3.6.2 Distribution of CURB65 Scores in patients admitted to ICU (N=15)
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3.7 Initial antibiotic therapy   
Empirical antimicrobial treatment was administered in the casualty on admission by 
the casualty officer. In the cohort of patients in whom empiric antimicrobial treatment 
was administered, 17 patients received amoxicillin-clavulanic acid and  one of 
fluoroquinolone, 10 patients received piperacillin-tazobactam and an 
aminoglycoside, six patients received cotrimoxazole, four patients received penicillin 
G and an aminoglycoside, four patients received ertapenem, four patients received 
ceftriaxone (three with cloxacillin and one without cloxacillin) and three patients 
received a fluoroquinolone (table 3.5).  
 
None of the patients received intravenous second-generation cephalosporins and an 
aminoglycoside or a macrolide.  
 
In HIV-infected patients presenting acutely with bilateral pulmonary ground glass 
infiltrates suspected to be due to Pneumocystis jirovecii, empirical therapy with 
cotrimoxazole was begun in 6 of the 48 patients with CAP.   
 
Three patients were empirically initiated on an intravenous fluoroquinolone on 
admission to casualty. 
 
 
 
 
 
 
70 
 
 
 
Table 3.5 Initial antibiotic therapy 
 
INTRAVENOUS ANTIBIOTIC  
 
NUMBER OF PATIENTS (N=48) 
 
Amoxicillin-clavulanic acid & a Fluoroquinolone 
 
 
17 
 
Piperacillin-tazobactam & an Aminoglycoside 
 
 
10 
 
Cotrimoxazole 
 
 
6 
 
Penicillin G & an Aminoglycoside 
 
 
4 
 
Ertapenem 
 
 
4 
 
Ceftriaxone ± Cloxacillin  
 
 
4 
 
Fluoroquinolone 
 
 
3 
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CHAPTER 4: DISCUSSION 
 
Four major findings are reported in this study.  Firstly, the total microbial yield was 
significantly improved in comparison to those reported previously (Jones et al., 
2010).  An initial aetiology based on culture positivity was present in only 27% of the 
study (n=13) which increased to 52.1% (n=25) with the use of a molecular platform.  
The aetiological yield improved with the implementation of nasopharyngeal secretion 
samples that were then stored in PrimeStore™ MTM for further analysis by PCR for 
respiratory viruses, bacterial and atypical pathogens.  Secondly, given that the major 
co-morbid factor in this cohort of patients was HIV (60.4%), it was notable that 
Streptococcus pneumoniae was still the leading causative agent of CAP (48%). 
Thirdly, despite respiratory viruses being found at a high frequency as part of a 
mixed infection, usually in combination with Streptococcus pneumoniae and 
Haemophilus influenzae; they were identified as the single pathogen in only 9 of 48 
patients with clinical and radiologically confirmed CAP.  Lastly, as the primary 
objective of this study was to describe the aetiology of CAP, the lack of atypical 
pathogens in this series was also noted.  One patient had a positive PCR for 
Mycoplasma pneumoniae in whom blood cultures and sputum cultures were 
negative but the clinical and radiological reporting was also indicative of PJP with a 
positive BDG>500.   
 
Attempting to establish a microbial aetiology for patients with CAP is challenging.  
Despite numerous studies to determine aetiology, the causative organisms are not 
found in almost half of the clinically diagnosed cases (Steinhoff et al., 1996). 
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In the present study, at least one aetiological agent was found in 39 of 48 cases 
(81.2%) with well-defined probable or definite microbial aetiology.  This high yield 
could be due to the 48 patients having undergone a complete sampling schedule 
and no antibiotics given prior to hospital admission.  This study was conducted 
during the winter months of the year when viral infections are also more common.  
The yield improved from 27% to 52.1% with the addition of PCR testing of 
nasopharyngeal secretion samples to the traditional diagnostic procedures.  These 
had been stored in a medium ideal for clinical collection and transport that preserves 
the released nucleic acids.  In addition to preserving labile RNA for testing it also 
contains an internal positive control capable of tracking the degradation of the 
sample from the point of collection.  Diagnosis of viral pneumonia can be 
challenging. Many viruses do not grow easily in culture and serum antibody testing is 
often not clinically useful. RNA is rapidly degraded after cell death.  Traditional 
culture techniques detects only viable organisms, unlike PCR, which does not need 
to distinguish between living and dead organisms thus making this novel transport 
medium a crucial diagnostic entity.   It is possible that the higher diagnostic yield for 
the viruses detected from our patients is due to the material that prevents the 
degradation of RNA in the PrimeStore™ MTM. 
 
This novel molecular transport medium allows researchers the flexibility to collect 
specimens and safely ship them to laboratories without expensive and cumbersome 
cold chain packaging.  For future studies and innovations, the PrimeStore™ MTM 
could facilitate standard sequencing and meta-genomic analysis of samples by 
improving the quality of the microbial nucleic acids in the collected specimens when 
they finally arrive in the laboratory.  It would be of value to have an active 
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comparison between our traditional viral nasopharyngeal swabs in order to validate 
the PrimeStore™ MTM nasopharyngeal swab.  The only limitation with this transport 
medium currently, is the economic implications of its use, especially within a 
resource constrained setting such as ours.  Despite the potential to offer great 
promise for improving diagnostic speed and accuracy, for tracking community and 
nosocomial outbreaks, several limitations currently hinder the widespread 
implementation of PrimeStore™ MTM.  The processing of this specific sample is fully 
dependent on a molecular platform and the initial cost to set up such a platform is 
expensive and unlikely to be standard in the near future.  These issues need 
solutions before many of these specialised molecular based storage media can be 
adopted in clinical practice on a regular basis (Stralin et al., 2006).   
 
A limitation of our study was the use of multiplex PCR that analysed multiple 
pathogens simultaneously.  The multiplex approach has been shown to lack 
sensitivity in comparison with monoplex techniques (Gröndahl et al., 1999). 
Alternative strategies minimising the competition between the probes have been 
developed to allow for primer pairs to be mixed in the same reaction tube without 
loss of sensitivity.  Stralin et al., (2006) compared conventional culture techniques to 
multiplex PCR for Streptococcus pneumoniae, Haemophilus influenzae, Mycoplasma 
pneumoniae and Chlamydophila  pneumoniae.  In the examination of sputum and 
nasopharyngeal samples from adults with CAP sensitivity ranged from 58 to 100% 
and specificity from 42 to 100%, depending on the organism and the type of sample.   
 
Although these molecular based techniques are sensitive compared to traditional 
culture methods, absolute pathogen detection is relatively low.  One study reported 
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that real-time quantitative PCR identified only 37.7% of pathogens in the patients 
with clinically diagnosed pneumonia (Kais et al., 2006).  PCR multiplex assays have 
been shown to exhibit an important range of positive results, the greatest difficulty 
was to recognise which pathogen is the cause of the community acquired 
pneumonia and whether the association could play a role in the severity of the 
disease. 
 
Blood samples for culture are not technically demanding and provide a definite 
microbial diagnosis when the results are positive, but in the present study, they 
revealed the aetiology of infection for only 16.7% of all patients, a percentage similar 
to previous studies (Woodhead et al., 1987).  Urine specimens are also easy to 
obtain, and Legionella pneumophila antigen assays are generally considered 
specific.  However, this test did not provide a diagnosis for any of our patients. We 
haven’t assessed the Streptococcus pneumoniae urinary antigen assay.   
 
Legionella pneumophila infections are relatively uncommon in HIV-positive CAP 
patients (Casau, 2004).  Most HIV positive patients receive cotrimoxazole as 
prophylactic treatment for various pathogens and the intrinsic antimicrobial activity of 
cotrimoxazole against Legionella pneumophila might account for this low yield in the 
majority of our patients but it certainly does not explain the poor yield in the HIV 
negative patients.  There are two possible explanations for the low yield in both 
patient groups.  Firstly, they could be false negative results due to Legionella species 
other than Legionella pneumophila serogroup 1, the latter accounting for about 80% 
of all cases of CAP caused by Legionella species (Wimberley et al., 1979) and 
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secondly, the yield is accepted to be low in adults with non-bacteraemic pneumonia 
(Bartlett, 2011). 
 
The strengths of this study include the study population and complete sampling 
schedule.  The study population reflects the group of patients referred for more 
complicated disease in which new diagnostic approaches are needed, i.e. HIV 
positive individuals.  It is interesting to note that our study’s aetiological spectrum 
was rather different from the previously mentioned study in South Africa in 1987, yet 
the antimicrobial guidelines have remained fairly similar.  The reason for the 
differences noted in previous studies is difficult to ascertain.  One possibility is that 
those studies included patients with co-morbid pathology known to be associated 
with invasive Gram-negative bacteria causing diseases.  Another reason could be 
that the data from 1987 did not reflect a major proportion of the population since this 
country was still in an apartheid era and only white patients were admitted.  It was 
also before the AIDS epidemic began in South Africa.  
 
In view of the limited size of this study, it provides incomplete information on the 
burden of CAP.  Aetiological data from developed countries may not be applicable to 
South Africa as a whole, because of country-specific differences in disease 
management, cost constraints and hospital admission criteria.  South Africa has a 
patient profile which makes us unique.  Additionally, data on epidemiology may be 
skewed if extrapolated for use in our developing setting.  Characteristics of patients 
in this study are not similar to those reported in previous studies.  In previous 
studies, the majority of the patients who developed community acquired pneumonia 
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were the elderly with heart disease, COPD, renal failure, diabetes and immune-
compromised (Niederman et al., 2001). 
 
Due to the unavailability of a routine viral diagnostic laboratory, traditional viral 
culture methods were not performed in our patients.  More research with regards to 
viral quantification may be useful in cases when a virus is the only potential 
pathogen detected (Martin et al., 2008).  The clinical correlation of the detection of a 
virus from the nasopharynx can be challenging.  The virus originates from an upper 
respiratory tract infection and may not be the cause of CAP even as detection of 
virus can generally be assumed to indicate infection of the lower respiratory tract 
(Pavia, 2011).  Viral quantification may be able to determine when a pathogen is 
associated with severe disease but more data using standardised methods are 
needed to validate cutoff values (Martin et al., 2008).  
 
Although it was mentioned earlier that CAP caused by Streptococcus pneumoniae 
has been reported in severely ill patients with higher CURB-65 scores (Rello, 2008) 
no such association could be found in our analysis by CURB-65 score.  Also of 
concern are patients initially triaged with low CURB-65 scores who subsequently 
deteriorated and required ICU admission.  With regards to Streptococcus 
pneumoniae as the main pathogen detected on blood culture, it was noted that in all 
cases they were initially triaged with low CURB-65 scores but subsequently 
deteriorated and required ICU admission.  
 
This finding may reflect an underestimation of the significance of the pathogen 
detected with regards to its potential for virulence or possibly that some elderly and 
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severely disabled patients were not admitted to the ICU due to prognostic 
considerations despite a moderate CURB-65 score which was mistaken since the 
prognostic score cannot replace clinical insight.  
 
It is possible that we are failing to recognise the important influence of the 
aetiological agent on the severity of disease (irrespective of severity index score) as 
well as repeatedly failing to evaluate aetiology as a prognostic indicator requiring 
extra clinical judgment.  The recognition of the aetiological pathogens of CAP should 
thereafter be alerting the clinician to the need for appropriate empiric antibiotic 
therapy. 
 
 In all instances overall clinical judgment is crucial.  Social factors and patients’ 
wishes also influence where to manage a patient.  Whether the CURB-65 score 
should be applied in conjunction with different management strategies to improve 
clinical outcomes and health service utilisation in our resource constrained setting 
requires further study.  For example a low serum albumin has been previously 
identified as an independent prognostic variable in addition to the CURB-65 score 
(Lim et al., 2003).  This would be an interesting outcome to analyse in view of our 
patients’ predominant HIV seropositivity co-morbid factor.   
 
 In view of South Africa’s introduction of PCV 7 (conjugate polysaccharide vaccine), 
which contains seven serotypes (4, 6B, 9V, 14, 18C, 19F and 23F), to the Extended 
Programme of Immunisation, despite this study’s limited size it was interesting to 
note that the majority of this study’s Streptococcus pneumoniae serotype distribution 
did not include the accepted virulent vaccine strains.  This could indicate that with 
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the use of PCV7 in South Africa we are already witnessing the increase carriage of 
and disease from serotypes not included in the vaccine.  Replacement has occurred 
in trials of pneumococcal vaccines (Lipsitch, 1999).  One of the blood culture 
confirmed isolates was missing from the NICD serotyping database.  It is possible 
that the isolate was not sent for further typing.   
 
In order to limit the development of resistance, the South African guidelines explicitly 
state that fluoroquinolones should not be used as routine first-line therapy for CAP, 
but rather be reserved for patients with proven Streptococcus pneumoniae CAP with 
severe allergy to standard beta-lactam agents and for known or suspected cases of 
infection with highly penicillin-resistant pneumococci.   
 
Upon review of patient records, none of the patients were treated according to South 
African guidelines.  It was worrying information that the chosen fluoroquinolone was 
ciprofloxacin and not one of the newer agents.  
 
Not a single patient that was empirically initiated on an aminoglycoside was followed 
up with trough serum drug levels despite 11 of the 17 (65%) patients being admitted 
in frank renal failure and two of the 17 patients being over the age of 70.  The South 
African guidelines clearly state that aminoglycosides should be discontinued if 
organisms other than Gram-negative bacteria are isolated.  All 17 patients received a 
minimum of 5 days of aminoglycosides.  Ertapenem was inappropriately initiated as 
empiric treatment in 4 patients who had not failed standard first-line antibiotic therapy 
for CAP and with no microbiological guidance.   None of the patients that met the 
criteria for suspected atypical pneumonia were treated with a macrolide.   
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Guidelines are useful  if they are followed and shown to alter prognosis in patience 
outcome .  It was concluded that non adherence to guidelines when selecting 
empirical antibiotic therapy, particularly amongst patients classified as having severe 
pneumonia, was associated with a higher mortality (Menendez et al., 2005).  Another 
study concluded that guideline implementation decreased the number of low risk 
patients that are hospitalised but might lead to patients being managed 
inappropriately in the community with some reports of over 25% of patients being 
treated with inappropriate antibiotic therapy (Yealy et al., 2005).  These varying 
practices are fully dependent on the maturity and insight of physicians as well as the 
hospital rules and regulations with disregard to guidelines.  The adherence rate 
amongst intensive care units is quoted as low as 67% (Menendez et al., 2005). 
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CHAPTER 5: CONCLUSION 
 
 Collection and transport of samples are key components of determining the 
aetiology of CAP.  Effective treatment and management relies on rapid, high quality 
PCR results with improved safety, whilst at the same time maintaining high 
sensitivity and specificity.  The reliable rapid testing significantly improves the quality 
and suitability of care that could be provided; both for inpatient and outpatient 
management.  
 
Regarding diagnostic tests they need to be utilised properly.  The availability of a 
more sensitive assay does not guarantee that it will be placed into practice 
appropriately.  The clinician must be able to interpret the results in the context of the 
diseases and thereafter determine management appropriately. 
 
Streptococcus pneumoniae as an aetiological agent of CAP may indicate severity of 
disease and need for critical care but this crucial point may be missed if the 
low/moderate CURB-65 score is the sole index for severity.  This study highlights the 
need to evaluate aetiology as a prognostic indicator since it is unclear what these 
severity scores truly reflect in isolation. 
 
The use of antibiotics may depend more on financial constraints than on available 
aetiological epidemiological data.  In cases in which the infecting pathogen can be 
identified, directed therapy should be employed.  The early and rapid initiation of 
empiric antimicrobial treatment should be based on an epidemiological approach, 
and these factors are essential for the adequate management of CAP. 
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APPENDIX 1 
 
INFORMED CONSENT: 
 
I hereby confirm that I have been informed by the study doctor, Dr Parastu Meidany about the nature, 
conduct, benefits and risks of clinical study THE MICROBIAL AETIOLOGY OF COMMUNITY-
ACQUIRED PNEUMONIA IN ADULTS IN JOHANNESBURG  
• I have also received, read and understood the above written information (Participant Information 
Leaflet and Informed Consent) regarding the clinical study. 
• I am aware that the results of the study, including personal details regarding my sex, age, date of 
birth, initials and diagnosis will be anonymously processed into a study report. 
• In view of the requirements of research, I agree that the data collected during this study can be 
processed in a computerised system by National Health Laboratory Services) or on their behalf.  
• I may, at any stage, without prejudice, withdraw my consent and participation in the study. 
• I have had sufficient opportunity to ask questions and (of my own free will) declare myself prepared to 
participate in the study.  
PARTICIPANT: 
 
                        Printed Name     Signature / Mark or Thumbprint  Date & Time 
I, herewith confirm that the above participant has been fully informed about the nature, conduct and 
risks of the above study. 
STUDY DOCTOR: 
 
Printed Name          Signature   Date & Time 
 
TRANSLATOR / OTHER PERSON EXPLAINING INFORMED CONSENT…………… 
(DESIGNATION): 
Printed Name    Signature    Date and Time 
WITNESS (If applicable): 
Printed Name    Signature    Date & Time 
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APPENDIX 2 
 
COMMUNITY ACQUIRED PNEUMONIA STUDY 
QUESTIONNAIRE AND DATA SHEET FOR PATIENTS ADMITTED WITH CAP 
 
Patient’s demographic data 
Date of admission (DD/MM/YYYY)  
                               / /  
  
Date of birth (DD/MM/YYYY)  
                      / /  
Age  Y  M   Unknown  
Gender: 
 Female      Male      Unknown  
Patient Hospital Number    
 
Start date of interview (DD/MM/YYYY): 
                        / /  
Diagnosis of CAP  
Confirmed  by chest X-ray    Not confirmed by chest X-ray  
                                                 
Date of specimen collection: (MM/DD/YYYY) 
   / /  
 
Where were you born? (Please circle)  
Urban (town-with electricity and running water)              
Rural (village no running water and no electricity)  
1. Soweto 
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2. JB city  
3. Gauteng – (Please specify) 
      4.  Other (Please specify) 
      5. Nursing home resident      (exclusion criteria)                               
What is the highest standard you passed at school? (Please tick) 
Grade   1,     2,    3,    4,    5,    6,   7,    8,    9,   10,   11, 12, none 
 
Are you?    (Please tick) 
Living alone                  Living with long-term partner     
                       
Are you employed? (Please tick) 
 Unemployed       Temporarily      Permanently          Part time          Full time 
                                                                    
 Describe your usual or past occupation.  
 
Describe what your usual workplace does or did? 
 
 
 
 
Patient’s social history 
Have you ever smoked cigarette or pipe regularly? (Please circle) 
 
                         
If yes: in the past five to ten years, how many would you usually smoke in a day?  
Cigarettes  Cigar  Pipes  
Pack/s: Number: Yes/no 
                                                                                    
Never In the past Yes now 
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How old were you when you first started smoking regularly? 
                                                                                 
 
About how much wine, beer or spirits did you drink on average each week?  
Beer Wine Other None 
1 large 
glass 
 
2 large 
glasses 
3 large 
and more 
Other 1 glass 2 
glasses 
  
 
ON EXAMINATION  
Vitals on day of admission 
Confusion:   Yes              No  
 
Blood pressure: systolic = 
 
Blood pressure: diastolic = 
 
Pulse rate= 
 
Respiratory rate= 
 
Temperature= 
 
CURB 65 score = 
 
ICU ADMISSION:    Yes                      No   
Date of ICU Admission:   
Blood pressure at the time of admission:                                                                                                                                                                                                 
Year old:        
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Inotrope Use:  Yes                      No  
Mental State:   
Alert:    Yes                      No   
Disorientated:   Yes                      No   
Stuporous / Coma:  Yes                      No  
 
Radiological findings-criteria   
1. Classification of findings 
a. Significant pathology*                 Yes                              No 
b. If yes, end-point consolidation  (consolidation containing air bronchograms)     Yes            
No 
c. Parenchymal consolidation     Yes            No 
d. Reticular or reticulonodular infiltrate     Yes            No 
e. Broncovascular bundle thickening     Yes            No 
f. Cavitation     Yes            No 
g. Other (non-end-point ) infiltrate (interstitial infiltrate and minor patchy infiltrate)     Yes                     
         No 
i. Unilateral                       
ii. Bilateral                           
iii. Single lobe     
iv. Multiple lobe                         
h. Pleural effusion     Yes                              No 
i. Adenopaties     Yes            No 
*Presence of consolidation, infiltrate or effusion if none no further recording.  
Underlying conditions (Please tick): 
Conditions YES NO 
Diabetes mellitus   
COPD   
Heart failure   
Renal failure acute   
Renal failure chronic   
Steroids use   
Liver failure   
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HIV status: 
Positive          Negative     Unknown 
                                           
CD4 count:                           Date CD4 count performed: (DD/MM/YYYY)  
                            / /  
Viral load:                            Date Viral load performed:     (DD/MM/YYYY)  
                                                                                             / /                                             
 
MICROBIOLOGY RESULTS 
SPECIMEN TYPE                TICK 
Sputum MC&S  
Nasopharyngeal swab  
Urine Legionella Ag  
Blood culture MC&S  
BDG  
Blood for U&E and FBC   
 
Sputum microscopy result: 
Bartlett score:  
Organisms seen: 
Culture results: 
Organism isolated  Specimen type 
Malignancy   
If yes malignancy specify which   
Splenectomy   
Other immunosuppresive therapy   
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1  
2  
 
 
SENSITIVITY PATTERN OF GRAM POSITIVE ISOLATE/S (MIC Value) 
1. Organism:                                    2: Organism: 
Penicillin  Penicillin  
Cephalosporin 3rd  Cephalosporin 3rd  
Erythromycin  Erythromycin  
Clindamycin  Clindamycin  
Tetracycline  Tetracycline  
Ciprofloxacin  Ciprofloxacin  
Moxifloxacin  Moxifloxacin  
Levofloxacin  Levofloxacin  
Linezolid  Linezolid  
Vancomycin  Vancomycin  
Synercid  Synercid  
Bactrim  Bactrim  
Chloramphenicol  Chloramphenicol  
Rifampicin  Rifampicin  
Gentamicin  Gentamicin  
Fusidic acid  Fusidic acid  
D zone (yes/no)  D zone (yes/no)  
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SENSITIVITY PATTERN OF GRAM NEGATIVE ISOLATE/S (MIC value) 
1. Organism                                2. Organism 
Ampicillin  Ampicillin  
Cefuroxime   Cefuroxime  
Augmentin  Augmentin  
TZP  TZP  
Cefazolin  Cefazolin  
Tetracycline  Tetracycline  
Ciprofloxacin  Ciprofloxacin  
Cefriaxone   Cefriaxone  
Ceftazidime  Ceftazidime  
Levofloxacin  Levofloxacin  
Cefepime  Cefepime  
Gentamicin  Gentamicin  
Amikacin  Amikacin  
Bactrim  Bactrim  
Tobramicin  Tobramicin  
Ertapenem  Ertapenem  
Imipenem  Imipenem  
Meropenem  Meropenem  
ESBL POS  ESBL POS  
 
 
Antimicrobial treatment 
Antibiotic Route Date started  Date stopped 
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TB treatment:  Y/N 
Empirical Treatment: Y / N  MONO Rx / COMBO Rx   
Definitive treatment: Y / N  MONO Rx / COMBO Rx   
Date of Change: 
Definitive Therapy within 48 H after Blood Culture: Y / N 
Persistence of fever for 48 H after definitive therapy: Y / N 
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APPENDIX 3 
 
 
 
(Lim et al., 2003) 
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APPENDIX 4 
 
 
(Niederman et al., 2001) 
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